The twice-a-year jab , called inclisiran, was approved for use on the NHS in 2021 for patients with stubbornly high cholesterol levels who have already suffered a heart attack. The twice-a-year jab , called inclisiran, was approved for use on the NHS in 2021 for patients with stubbornly high cholesterol levels who have already suffered a heart attack.